The following is a summary of "Real-world comparison of T2-biologics effectiveness in severe allergic asthma with nasal ...

Patients with severe asthma required fewer steroid bursts with tezepelumab-ekko, according to a poster presented at the 2025 American Academy of Allergy, Asthma & Immunology/World Allergy Organization ...

Based on the advice from the FDA at the meeting, Connect plans to begin enrolling patients in these trials during the second quarter of this year.

Eosinophilic asthma is a more severe subtype of asthma. Treatment options include inhaled and oral corticosteroids, leukotriene modifiers, and biologics. Eosinophilic asthma is a subtype of asthma ...

For individuals with severe asthma, biologics—a new type of treatment targeting specific mechanisms in the immune system—have been shown to reduce asthma attacks, lower the need for ...

Adherence was deemed intermittent based on heatmaps. SAN DIEGO — Across six asthma biologics, adherence differed by the therapy given and was often low or irregular based on three adherence ...

In a phase 4 trial, dupilumab effectively reduces airway inflammation and mucus plugging, improving lung function and asthma control in patients with moderate to severe type 2 asthma.

Severe asthma is a chronic respiratory condition in which your symptoms are more intense and difficult to control than mild-to-moderate cases. Treatments include corticosteroids, biologics ...

In the SWIFT and ANCHOR trials, depemokimab demonstrated statistically significant reductions in nasal polyp size, obstruction, and asthma exacerbations compared to placebo. The FDA has accepted GSK’s ...

Are you up-to-date on the latest guidance for severe asthma management? Test yourself with this quick quiz.